medigraphic.com

2005, Number 4

<< Back Next >>

Rev Mex Anest 2005; 28 (4)

Comparison of sustained-released vs. immediate-release tramadol in patients with cancer pain

Guajardo-Rosas J, Plancarte-Sánchez R, Mayer-Rivera FJ, Acosta-Quiroz CO

Language: Spanish
References: 12
Page: 198-202
PDF size: 57.33 Kb.


ABSTRACT

Objective: To assess certain features of sustained-release and immediate-release tramadol based on clinical profile, such as pain relief, average number of rescues, total daily dose, side effects, and which formulation achieves a better control of pain. Methods: Patients with cancer pain were given tramadol 200 mg/day in either of two formulation in order to asses the number of rescue doses, side effects and intensity of pain in a visual analogue scale. Results: Immediate-release and sustained-release tramadol were given to 20 patients each. Baseline VAS assessment showed no statistically significant difference. In the first group, pain relief began at 44.5 minutes, and in the second group, at 200 minutes. At 7 days, the mean rescue doses was 3.1 and 1.0 in each group, and the total daily dose was 277.5 mg for Group 1 and 230 for Group 2. Conclusions: Sustained-release tramadol achieves a similar control of pain compared to immediate-release tramadol, but with a lower total daily dose and an easier administration.


REFERENCES

  1. Raber M, Hoffman S, Junge K, et al. Analgesic efficacy and tolerability of tramadol 100 mg sustained-release capsules in patients with moderate to severe chronic low back pain. Clin Drug Invest 1999;17:415-423.

  2. Angst M, Drover D, Lötsch J, Ramaswamy B, et al. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology 2001;94:63-73.

  3. Raber M, Schulz HU, Schürer M, et al. Pharmacokinetic properties of tramadol sustained release capsules. Arzneim-Forsch/Drug Res 1999;49:588-593.

  4. Reisine T, Pasternak G. En: Las bases farmacológicas de la terapéutica. 9ª ed. (Hardman J, Limbird L, Molinoff P, Goodman A.) McGraw-Hill Interamericana, 1996.pp. 557-593.

  5. Bozzini L, Hill E. Drugdex. 2001. Micromedex.

  6. Backonja M. En Bonica´s management of pain. 3a edition. (Loeser J, Butler S, Chapman R, Turk D.) Lippincott Williams e Wilkins 2001.pp 371-387.

  7. Fausett H, Warfield C. En: Manual of pain management. 2a ed. (Fausett H, Warfield C.) Lippincott Williams & Wilkins, 2002.pp. 237-242.

  8. Soucy C, Albrecht J, Brown-Wagner S, Carey L, et al. Drug therapy for pain. Springhouse, 2001.pp. 37-72.

  9. Shipton EA. Tramadol – present and future. Anaesth Intensive Care 2000;28:363-374.

  10. Grond S, Radbruch L, Meuser T, et al. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage 1999;18:174-179.

  11. Harati Y, Gooch C, Swenson M, et al. Maintenance of the long term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 2000;14:65-70.

  12. Oviasu VO, Oli JM, Onyemelukwe GC. A multicentre clinical trial with the analgesic tramadol hydrochloride. Curr Ther Res 1984;36:29-32.




2020     |     www.medigraphic.com